Emicizumab treatment for children with hemophilia A
Part of Blood & lymphatic, Bones, joints & muscles, Genetic & congenital clinical trials.
This study tests a medicine called emicizumab, given as a shot under the skin, to see how well it works in children with hemophilia A. It may help prevent bleeding episodes and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 18 years old.
- You must have a doctor's diagnosis of hemophilia A.
- Your factor level (a protein that helps blood clot) must be 1% or less.
- You may have inhibitors (antibodies that block treatment) or not.
- You must be able to start subcutaneous (under the skin) treatment with emicizumab.
- You must be willing to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
This trial compares two low-dose medicines to prevent bleeding episodes in people with severe hemophilia A: a newer medicine (emicizumab) versus the standard factor VIII treatment. It may help find a more convenient or effective way to reduce bleeding.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.